Global Europe Biosimilars Market Size, Share and Trends Analysis
Europe biosimilars market valued at $28.0B in 2023, projected to reach $78.0B by 2032 at 12% CAGR.
$28.0B
$77.7B
12%
North America
Executive Summary
The European biosimilars market, valued at approximately $28.0 billion in 2023, is set to expand to $78.0 billion by 2032, reflecting a 12% CAGR. Growth is driven by patent expiries, cost‑containment policies, and rising adoption of biologic therapies across oncology and autoimmune indications.
Key Highlights
Europe’s biosimilar market expected to surpass $78B by 2032 at 12% CAGR.
Monoclonal antibodies dominate product mix, holding ~45% share.
Germany leads adoption, driven by strong reimbursement frameworks.
Market Overview
Market Context
Europe represents a third of the global biosimilars market, propelled by patent expiries and cost‑containment policies. Regulatory harmonisation across the EU accelerates approvals and market entry.
Europe accounts for roughly 35% of the global biosimilars market, with Germany, France and the UK leading adoption. The market is in a high‑growth phase, transitioning from early adopter to mainstream uptake.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$28.0B
Forecast (2032)
$77.7B
CAGR (2024-2032)
12%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $28.00B |
| 2024 | $31.36B |
| 2025 | $35.12B |
| 2026 | $39.34B |
| 2027 | $44.06B |
| 2028 | $49.35B |
| 2029 | $55.27B |
| 2030 | $61.90B |
| 2031 | $69.33B |
| 2032 | $77.65B |
Applying a 12% CAGR from the 2023 base of $28.0B yields a $77.7B market by 2032, reflecting sustained demand from oncology, autoimmune, and emerging therapeutic areas.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 45.0% | 10.0% | United States |
| Europe | 35.0% | 12.0% | Germany |
| Asia Pacific | 20.0% | 15.0% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Patent cliffs for major biologics
- Government initiatives to lower healthcare costs
- Expanding clinical evidence supporting biosimilar safety
Market Segmentation
| Segment | Share |
|---|---|
| Monoclonal AntibodiesDominant segment driven by oncology and autoimmune biosimilar launches. | 45.0% |
| Recombinant ProteinsIncludes insulin and growth factor biosimilars with strong demand. | 30.0% |
| PeptidesGrowing adoption in endocrinology and metabolic therapies. | 15.0% |
| OthersCovers vaccines, blood factors, and small‑molecule biosimilars. | 10.0% |
| Total | 100.0% |
By End User
- Hospitals
- Specialty Clinics
- Research Institutes
Regional Analysis
North America
Lead: United StatesMature market with high biosimilar uptake in oncology and supportive reimbursement policies.
Europe
Lead: GermanyFast‑growing segment driven by EU regulatory harmonisation and cost‑containment initiatives.
Asia Pacific
Lead: ChinaEmerging market with rapid biosimilar approvals and expanding healthcare infrastructure.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| Germany | 12.0% | +13.0% |
| France | 8.0% | +11.5% |
| United Kingdom | 7.0% | +10.8% |
Competitive Landscape
Sandoz
Switzerland
Largest biosimilar portfolio globally, strong EU presence and broad therapeutic coverage.
World’s largest biosimilar manufacturer with a broad portfolio across oncology, immunology and growth disorders.
Pfizer
United States
Leverages Hospira legacy and robust pipeline to capture growing biosimilar share in Europe.
Leverages Hospira’s biosimilar assets and strong R&D to capture key EU market segments.
Novartis (via Hexal)
Switzerland
Focused biosimilar unit targeting oncology and immunology segments across EU.
Focused biosimilar unit targeting high‑volume oncology and immunology indications in Europe.
Recent Developments
Launched interchangeable biosimilar for adalimumab across EU.
Acquired CIMERLI ophthalmic biosimilar portfolio to expand EU presence.
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
High‑growth opportunity in EU biosimilar segment, especially in monoclonal antibodies.
Focus on regulatory alignment and payer partnerships to capture market share.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- PharmaceuticalsGlobal Biosimilars Market$26.5B · 14.5% CAGR
- PharmaceuticalsGlobal Asia Pacific Biosimilars Market$30.3B · 13% CAGR
- PharmaceuticalsGlobal United States Biosimilars Market$30.3B · 10.9% CAGR
- PharmaceuticalsEurope RNA Therapeutics Market$19.6B · 11% CAGR
- PharmaceuticalsEurope Antibody Drug Conjugates Industry Size, Competitive Landscape and Regional Analysis$11.2B · 23.7% CAGR
- PharmaceuticalsGlobal North America Biosimilars Market$8.2B · 28.1% CAGR